Pro-lifers have long warned about the severe risks chemical abortion pills pose to women’s safety, but now, after the overturn of Roe, the abortion industry has upped its game when it comes to getting this dangerous drug into the hands of women. And recently, businesses that offer abortions have even gone so far as to start prescribing the abortion pill to non-pregnant women.
Last month, a spokesperson for the Food and Drug Administrative expressed concern to Politico about telehealth providers offering women an advance prescription of Mifepristone, the first drug women take in the chemical abortion pill regimen.
Mifepristone works by blocking the effects of the natural pregnancy hormone progesterone, depriving the unborn child of the nutrients it needs to survive. Typically, 24-48 hours later, a woman takes a second drug called Misoprostol, which triggers contractions and causes the woman to deliver the baby.
As the FDA spokesperson pointed out, if providers prescribe Mifepristone to a woman before she’s even pregnant, then there will be no way to assess whether her health is at risk.
Suppose a women takes mifepristone weeks or months after the prescription is filled without seeing a doctor. In that case, there is no way to determine if she’s experiencing an ectopic pregnancy or other potential pregnancy complications, endangering her life.
Cindy Adams, CEO of Choix, one the of the telemedicine providers offering advanced Mifepristone prescriptions, however, doesn’t see it that way.
Adam claims that chemical abortion pill restrictions are “unnecessary, and insists that the process is safe. She began offering abortion pills to non-pregnant women due to the court overturning Roe this summer as a way to expand access to it.
Another group that offers women Mifepristone before they’re pregnant is Aid Access, a Netherlands-based organization that has been doing this since the Texas Heartbeat Act took effect last year.
Proponents of the advanced provision of Mifepristone claim it’s necessary in case women intend to have a abortion sometime in the future and their state restricts access.
Btu they forget something crucial: Advanced provision of Mifepristone is not approved by the FDA, and providers prescribing the drug to non-pregnant women are acting without authorization.
Reprotection is fully aware of the dangers chemical abortions can pose to women’s health. According to a 2015 study published by Obstetrics & Gynecology titled “Incidence of Emergency Room Department Visits and Complications After Abortion,” chemical abortions have a higher complication rate than surgical abortions.
The study found that the complication rate was 5.2% for women who took the abortion pill compared to 1.3% for woman who had a first-trimester surgical abortion.
As an organization that exists to hold the abortion industry accountable by ensuring proper enforcement of the law, Reprotection is calling on the FDA to act before it’s too late. The FDA can take enforcement action by fining violators, seizing drugs, or imposing an injunction or civil money penalties.
The abortion industry cannot be allowed to continue skirting the law, especially when the lives of women and their unborn children are are stake.